&nbsp;

Aug 2024

Drug

oBINutuzumab

Other Name(s): Gazyva®

Quick Link(s):

May 2022

Regimen

IRIN+CETU; IRIN(Q2W)+CETU

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Cetuximab with Irinotecan - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

Drugs Used:

cetuximab,

irinotecan

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

IPIL

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Ipilimumab - Previously Untreated Advanced Unresectable Melanoma

New Drug Funding Program

Ipilimumab - Previously Treated Advanced Unresectable Melanoma

Drugs Used:

ipilimumab

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

OXALRALT

Cancer Type:

Gastrointestinal,

Colorectal,

Esophagus,

Gastric / Stomach,

Small bowel and appendix

Intent: Adjuvant, Palliative

Funding:

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

New Drug Funding Program

Raltitrexed - Adjuvant Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Adjuvant Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

raltitrexed,

oxaliplatin

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

IDEL+RITU; IDEL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria

New Drug Funding Program

Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

idelalisib,

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

IRINRALT

Cancer Type:

Gastrointestinal,

Colorectal,

Esophagus,

Gastric / Stomach,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

irinotecan,

raltitrexed

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

OBIN(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - Maintenance Treatment for Refractory Follicular Lymphoma

Drugs Used:

oBINutuzumab

Quick Link(s):

Regimen Monograph

Dec 2019

Regimen

INOT

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Palliative

Funding:

New Drug Funding Program

Inotuzumab Ozogamicin (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia

Drugs Used:

inotuzumab ozogamicin

Quick Link(s):

Regimen Monograph

Jul 2023

Drug

inotuzumab ozogamicin

Other Name(s): Besponsa®

Quick Link(s):

Jul 2023

Regimen

ICE+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Adjuvant, Curative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

Drugs Used:

mesna,

Quick Link(s):

Regimen Monograph

Dec 2020

Drug

isatuximab

Other Name(s): Sarclisa®

Quick Link(s):